316 related articles for article (PubMed ID: 22683083)
1. Comparative uterine effects on ovariectomized rats after repeated treatment with different vaginal estrogen formulations.
López-Belmonte J; Nieto C; Estevez J; Delgado JL; del Prado JM
Maturitas; 2012 Aug; 72(4):353-8. PubMed ID: 22683083
[TBL] [Abstract][Full Text] [Related]
2. Lasofoxifene enhances vaginal mucus formation without causing hypertrophy and increases estrogen receptor beta and androgen receptor in rats.
Wang XN; Simmons HA; Salatto CT; Cosgrove PG; Thompson DD
Menopause; 2006; 13(4):609-20. PubMed ID: 16837883
[TBL] [Abstract][Full Text] [Related]
3. The therapeutic effect of a new ultra low concentration estriol gel formulation (0.005% estriol vaginal gel) on symptoms and signs of postmenopausal vaginal atrophy: results from a pivotal phase III study.
Cano A; Estévez J; Usandizaga R; Gallo JL; Guinot M; Delgado JL; Castellanos E; Moral E; Nieto C; del Prado JM; Ferrer J
Menopause; 2012 Oct; 19(10):1130-9. PubMed ID: 22914208
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and preliminary efficacy of two vaginal gel formulations of ultra-low-dose estriol in postmenopausal women.
Delgado JL; Estevez J; Radicioni M; Loprete L; Moscoso Del Prado J; Nieto Magro C
Climacteric; 2016 Apr; 19(2):172-80. PubMed ID: 26786399
[TBL] [Abstract][Full Text] [Related]
5. The effects of hyaluronic acid vaginal gel on the vaginal epithelium of ovariectomized rats.
Liu SB; Liu SL; Gan XL; Zhou Q; Hu LN
Gynecol Endocrinol; 2015 Mar; 31(3):208-13. PubMed ID: 25366523
[TBL] [Abstract][Full Text] [Related]
6. Vaginal DHEA to treat menopause related atrophy: a review of the evidence.
Panjari M; Davis SR
Maturitas; 2011 Sep; 70(1):22-5. PubMed ID: 21733647
[TBL] [Abstract][Full Text] [Related]
7. Uterotrophic effects of tamoxifen, toremifene, and raloxifene do not predict endometrial cell proliferation in the ovariectomized CD1 mouse.
Carthew P; Edwards RE; Nolan BM
Toxicol Appl Pharmacol; 1999 Jul; 158(1):24-32. PubMed ID: 10387929
[TBL] [Abstract][Full Text] [Related]
8. Comparative responses of three rat strains (DA/Han, Sprague-Dawley and Wistar) to treatment with environmental estrogens.
Diel P; Schmidt S; Vollmer G; Janning P; Upmeier A; Michna H; Bolt HM; Degen GH
Arch Toxicol; 2004 Apr; 78(4):183-93. PubMed ID: 14689164
[TBL] [Abstract][Full Text] [Related]
9. Low-dose, vaginally administered estrogens may enhance local benefits of systemic therapy in the treatment of urogenital atrophy in postmenopausal women on hormone therapy.
Palacios S; Castelo-Branco C; Cancelo MJ; Vázquez F
Maturitas; 2005 Feb; 50(2):98-104. PubMed ID: 15653006
[TBL] [Abstract][Full Text] [Related]
10. Biochemical and histological effects of vaginal estriol and estradiol applications on the endometrium, myometrium and vagina of postmenopausal women.
van Haaften M; Donker GH; Sie-Go DM; Haspels AA; Thijssen JH
Gynecol Endocrinol; 1997 Jun; 11(3):175-85. PubMed ID: 9209898
[TBL] [Abstract][Full Text] [Related]
11. Effect of dehydroepiandrosterone on vaginal and uterine histomorphology in the rat.
Sourla A; Flamand M; Bélanger A; Labrie F
J Steroid Biochem Mol Biol; 1998 Aug; 66(3):137-49. PubMed ID: 9719448
[TBL] [Abstract][Full Text] [Related]
12. A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women.
Kagan R; Williams RS; Pan K; Mirkin S; Pickar JH
Menopause; 2010 Mar; 17(2):281-9. PubMed ID: 19779382
[TBL] [Abstract][Full Text] [Related]
13. Vaginal effects of ospemifene in the ovariectomized rat preclinical model of menopause.
Unkila M; Kari S; Yatkin E; Lammintausta R
J Steroid Biochem Mol Biol; 2013 Nov; 138():107-15. PubMed ID: 23665515
[TBL] [Abstract][Full Text] [Related]
14. Effects of lasofoxifene on the uterus, vagina, and breast in ovariectomized cynomolgus monkeys (Macaca fascicularis).
Cline JM; Botts S; Lees CJ; Brommage R
Am J Obstet Gynecol; 2008 Aug; 199(2):158.e1-8. PubMed ID: 18501325
[TBL] [Abstract][Full Text] [Related]
15. Activity of raloxifene in immature and ovariectomized rat uterotrophic assays.
Ashby J; Odum J; Foster JR
Regul Toxicol Pharmacol; 1997 Jun; 25(3):226-31. PubMed ID: 9237325
[TBL] [Abstract][Full Text] [Related]
16. Comparison of usefulness of estradiol vaginal tablets and estriol vagitories for treatment of vaginal atrophy.
Dugal R; Hesla K; Sørdal T; Aase KH; Lilleeidet O; Wickstrøm E
Acta Obstet Gynecol Scand; 2000 Apr; 79(4):293-7. PubMed ID: 10746845
[TBL] [Abstract][Full Text] [Related]
17. Vaginal atrophy in breast cancer survivors: role of vaginal estrogen therapy.
Mariani L; Gadducci A; Vizza E; Tomao S; Vici P
Gynecol Endocrinol; 2013 Jan; 29(1):25-9. PubMed ID: 22994445
[TBL] [Abstract][Full Text] [Related]
18. Using vaginal cytology to assess the estrogenic activity of phytoestrogen-rich herb.
Malaivijitnond S; Chansri K; Kijkuokul P; Urasopon N; Cherdshewasart W
J Ethnopharmacol; 2006 Oct; 107(3):354-60. PubMed ID: 16730147
[TBL] [Abstract][Full Text] [Related]
19. Estrogenic uterovaginal effects of oral estetrol in the modified Allen-Doisy test.
Heegaard AM; Holinka CF; Kenemans P; Coelingh Bennink HJ
Climacteric; 2008; 11 Suppl 1():22-8. PubMed ID: 18464018
[TBL] [Abstract][Full Text] [Related]
20. Topical estrogen therapy in the management of postmenopausal vaginal atrophy: an up-to-date overview.
Al-Baghdadi O; Ewies AA
Climacteric; 2009 Apr; 12(2):91-105. PubMed ID: 19117185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
